Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium
Silexion Therapeutics (NASDAQ: SLXN) has announced its upcoming presentation at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco from January 23-25, 2025. The company will present data on SIL-204, their RNA interference therapy targeting KRAS-driven cancers.
The presentation, titled 'SIL-204 siRNA free and encapsulated in extended release microparticles for the treatment of localized and systemic cancer that harbors a KRAS G12x, Q61H, or G13D mutation,' will be delivered by Mitchell Shirvan, Ph.D. during the Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract session on January 24, 2025, from 11:30 AM to 1:00 PM PST.
The abstract will be published on the symposium's website on January 21, 2025, at 5:00 p.m. ET, and the poster will subsequently be available on Silexion's website under the 'Our Science' section.
Silexion Therapeutics (NASDAQ: SLXN) ha annunciato la sua prossima presentazione al 2025 ASCO Gastrointestinal Cancers Symposium a San Francisco dal 23 al 25 gennaio 2025. L'azienda presenterà dati su SIL-204, la loro terapia di interferenza RNA che mira ai tumori guidati da KRAS.
La presentazione, intitolata 'SIL-204 siRNA libero e incapsulato in microparticelle a rilascio prolungato per il trattamento del cancro localizzato e sistemico che presenta una mutazione KRAS G12x, Q61H o G13D', sarà svolta da Mitchell Shirvan, Ph.D. durante la sessione sui Tumori del Pancreas, Intestino Tenue e Apparato Epatobiliare il 24 gennaio 2025, dalle 11:30 alle 13:00 PST.
L'abstract sarà pubblicato sul sito web del simposio il 21 gennaio 2025, alle 17:00 ET, e il poster sarà successivamente disponibile sul sito web di Silexion nella sezione 'La Nostra Scienza'.
Silexion Therapeutics (NASDAQ: SLXN) ha anunciado su próxima presentación en el Simposio de Cánceres Gastrointestinales ASCO 2025 en San Francisco del 23 al 25 de enero de 2025. La compañía presentará datos sobre SIL-204, su terapia de interferencia de RNA que se dirige a cánceres impulsados por KRAS.
La presentación, titulada 'SIL-204 siRNA libre y encapsulado en micropartículas de liberación prolongada para el tratamiento de cáncer localizado y sistémico que presenta una mutación KRAS G12x, Q61H o G13D', será presentada por Mitchell Shirvan, Ph.D. durante la sesión de Cánceres del Páncreas, Intestino Delgado y Tracto Hepatobiliar el 24 de enero de 2025, de 11:30 AM a 1:00 PM PST.
El resumen se publicará en el sitio web del simposio el 21 de enero de 2025 a las 5:00 p.m. ET, y el póster estará disponible posteriormente en el sitio web de Silexion en la sección 'Nuestra Ciencia'.
시렉시온 테라퓨틱스 (NASDAQ: SLXN)는 2025년 1월 23일부터 25일까지 샌프란시스코에서 열리는 2025 ASCO 위장관 암 심포지엄에서의 발표를 예고했습니다. 회사는 SIL-204에 대한 데이터를 발표할 예정이며, 이는 KRAS 주도 암을 표적으로 하는 RNA 간섭 요법입니다.
발표 제목은 'KRAS G12x, Q61H 또는 G13D 변이를 가진 국소 및 전신 암 치료를 위한 자유 및 캡슐화된 SIL-204 siRNA의 지속 방출 미세 입자에서'이며, 2025년 1월 24일 PST 기준 오전 11:30부터 오후 1:00까지 췌장, 소장 및 담도 관련 암 세션에서 미첼 시르반 박사에 의해 진행됩니다.
초록은 2025년 1월 21일 오후 5시에 심포지엄 웹사이트에 게시될 예정이며, 포스터는 이후 '우리의 과학' 섹션에서 시렉시온의 웹사이트에서 확인할 수 있습니다.
Silexion Therapeutics (NASDAQ: SLXN) a annoncé sa prochaine présentation au Symposium ASCO 2025 sur les Cancers Gastro-Intestinaux à San Francisco du 23 au 25 janvier 2025. L'entreprise présentera des données sur SIL-204, leur thérapie par interférence d'ARN visant les cancers liés à KRAS.
La présentation, intitulée 'SIL-204 siRNA libre et encapsulé dans des microparticules à libération prolongée pour le traitement du cancer localisé et systémique portant une mutation KRAS G12x, Q61H ou G13D', sera présentée par Mitchell Shirvan, Ph.D. lors de la session sur les cancers du pancréas, de l'intestin grêle et des voies hépato-biliaires le 24 janvier 2025, de 11h30 à 13h00 PST.
Le résumé sera publié sur le site web du symposium le 21 janvier 2025 à 17h00 ET, et l'affiche sera ensuite disponible sur le site de Silexion dans la section 'Notre Science'.
Silexion Therapeutics (NASDAQ: SLXN) hat seine bevorstehende Präsentation beim 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco vom 23. bis 25. Januar 2025 angekündigt. Das Unternehmen wird Daten zu SIL-204 präsentieren, ihrer RNA-Interferenztherapie, die gezielt KRAS-gesteuerte Krebserkrankungen anspricht.
Die Präsentation mit dem Titel 'SIL-204 siRNA frei und in verlängerten Freisetzung Mikropartikeln für die Behandlung von lokalisiertem und systemischen Krebs mit einer KRAS G12x, Q61H oder G13D Mutation' wird von Mitchell Shirvan, Ph.D., am 24. Januar 2025 während der Sitzung zu Pankreas-, Dünndarm- und hepato-biliären Tumoren von 11:30 bis 13:00 Uhr PST gehalten.
Das Abstract wird am 21. Januar 2025 um 17:00 Uhr ET auf der Website des Symposions veröffentlicht, und das Poster wird anschließend auf der Website von Silexion im Abschnitt 'Unsere Wissenschaft' verfügbar sein.
- None.
- None.
Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers
Cayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it will be presenting a poster at the 2025 ASCO Gastrointestinal (GI) Cancers Symposium taking place January 23-25, 2025, in San Francisco, California.
The 2025 ASCO Gastrointestinal Cancers Symposium is a specialized meeting designed to highlight the latest science in GI cancers and other information oncologists of all subspecialties need to know now, in order to provide the highest quality of care to patients.
Silexion’s abstract will be published on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025. Following the presentation, the poster will be available on Silexion Therapeutics’ website under the “Our Science” section.
Presentation Details
Title: SIL-204 siRNA free and encapsulated in extended release microparticles for the treatment of localized and systemic cancer that harbors a KRAS G12x, Q61H, or G13D mutation
Presenter: Mitchell Shirvan, Ph.D.
Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Abstract Number: 745
Session Date & Time: January 24, 2025, 11:30 AM-1:00 PM PST
About Silexion Therapeutics
Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com
Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Capital Markets & IR Contact
ARX | Capital Markets Advisors
North American Equities Desk
silexion@arxadvisory.com
FAQ
When will Silexion Therapeutics (SLXN) present their SIL-204 data at the 2025 ASCO GI Symposium?
What types of KRAS mutations does Silexion's SIL-204 therapy target?
When will the SLXN abstract be available for viewing?
What is the therapeutic approach of Silexion's SIL-204 treatment?